骨矿物质密度和TAVR结果:对增强型和非增强型TAVRCT扫描患者进行比较分析
Caglayan Demirel1, Kevin Hamzaraj1, Anna Seeber1
1Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Heart & lung : the journal of critical care
|November 14, 2024
概括
在非增强型CT扫描上测量的低骨矿物质密度 (BMD) 预测过导管大动脉置换 (TAVR) 后的生存率不佳. 与对比度增强的扫描没有显示这种关联,突出显示了TAVR患者评估中非增强的BMD的价值.
科学领域:
- 心脏病学 心脏病学
- 放射学 放射学是一门学科.
- 老年病的医生 老年病的医生
背景情况:
- 通过导管的大动脉置换 (TAVR) 的程序前评估至关重要,包括脆弱性评估.
- 计算机断层扫描 (CT) 扫描对于TAVR患者的身体组成分析是强制性的.
- 低骨矿物质密度 (BMD) 对TAVR结果的预后价值,特别是非增强型CT与对比增强型CT的预后价值,尚未得到充分确立.
研究的目的:
- 为了研究低骨质量对接受TAVR的患者的生存率的影响.
- 为了确定使用非增强和增强对比度的TAVRCT扫描来测量BMD的可行性.
主要方法:
- 分析了725名TAVR患者的队列,其中包括非增强型和对比增强型CT扫描 (2015年11月至2022年3月).
- 骨矿物质密度 (BMD) 在两个扫描类型上使用Hounsfield单位 (HU) 量化胸椎水平;低BMD被定义为<200 HU.
- 考克斯回归分析用于调整与骨质疏松症相关的混因素.
主要成果:
- 在非增强型CT扫描中较低的BMD与TAVR后的生存率降低显著相关 (p=0.046),即使在对骨质疏松症预测因素进行调整后也是如此.
- 相比之下,在使用对比度增强的CT扫描 (p=0.830) 进行评估时,没有发现低BMD和存活率之间的显著关联.
结论:
- 在非增强型TAVR-CT扫描上进行机会性骨损伤评估是可行的,并预测TAVR后的不良结果.
- 将非增强型骨质量测量整合到程序前TAVR评估中可以增强脆弱性评估.
- 低BMD和TAVR结局之间的关联与非增强型CT成像特异.
相关概念视频
Imaging Studies for Cardiovascular System V: CT
3
Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
3
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
3
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
3


